Treatment of cryptogenic new-onset refractory status epilepticus (C-NORSE) with tocilizumab: A case report-Reference-Cited by-同舟云学术

Treatment of cryptogenic new-onset refractory status epilepticus (C-NORSE) with tocilizumab: A case report

Published:2024 Issue: Volume: Page:
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Nakamura Yumiko¹,Ueda Masayuki¹,Kodama Satoshi¹,Kimura Tomohiko¹,Shirota Yuichiro¹²,Hamada Masashi¹,Ishiura Hiroyuki¹,Iizuka Takahiro³,Toda Tatsushi¹

Affiliation:

1. Department of Neurology, Graduate School of Medicine, The University of Tokyo, Japan

2. Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Japan

3. Department of Neurology, Kitasato University School of Medicine, Japan

Publisher

Japanese Society of Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_3392-23/_pdf

Reference14 articles.

1. 1. Hirsch LJ, Gaspard N, van Baalen A, et al. Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions. Epilepsia 59: 739-744, 2018.

2. 2. Hanin A, Cespedes J, Dorgham K. Cytokines in new-onset refractory status epilepticus predict outcomes. Ann Neurol 94: 75-90, 2023.

3. 3. Gaspard N, Foreman BP, Alvarez V, et al. New-onset refractory status epilepticus: Etiology, clinical features, and outcome. Neurology 85: 1604-1613, 2015.

4. 4. Wickstrom R, Taraschenko O, Dilena R, et al. International NORSE Consensus Group. International consensus recommendations for management of new onset refractory status ppilepticus (NORSE) including febrile infection-related epilepsy syndrome (FIRES): Statements and Supporting Evidence. Epilepsia 63: 2840-2864, 2022.

5. 5. Gall CR, Jumma O, Mohanraj R, et al. Five cases of new onset refractory status epilepticus (NORSE) syndrome: outcomes with early immunotherapy. Seizure 22: 217-220, 2013.